12:00 AM
Jul 23, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ReZolve Bioresorbable Sirolimus-Eluting Coronary Scaffold: Completed pilot trial enrollment

Reva completed enrollment of 26 patients with symptomatic coronary artery disease due to one or more discrete areas of blockage in the open-label, international RESTORE pilot trial evaluating...

Read the full 120 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >